New Weight-Loss drug bofanglutide takes on semaglutide in major trial

NCT ID NCT07622810

Not yet recruiting Disease control Sponsor: Carnot Laboratories Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called bofanglutide (GZR18) against the existing drug semaglutide for weight loss in 352 Latin American adults with overweight or obesity. Participants receive injections every two weeks (bofanglutide) or weekly (semaglutide) for 36 weeks, along with diet and exercise advice. The main goal is to see if bofanglutide leads to greater weight loss and improvements in health measures like blood sugar and cholesterol.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

CICMEX Centro de Investigación Clínica de México S de RL de CV.

Morelia, Michoacán, 58000, Mexico
Centro de Estudios de lnvestigación Metabólicos y Cardiovasculares, S.C.

Ciudad Madero, Tamaulipas, 89440, Mexico
Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

Guadalajara, Jalisco, 44340, Mexico
Instituto Nacional de Cardiología "Ignacio Chávez"

Mexico City, 14080, Mexico
Investigación Médica Sonora S.C.

Hermosillo, Sonora, 83280, Mexico
SMIQ, S. de R.L. de C.V.

Querétaro City, Querétaro, 76070, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.